Dong-A grants AbbVie rights to MERTK inhibitor

Dong-A ST Co. Ltd. (KSE:170900) granted AbbVie Inc. (NYSE:ABBV) exclusive rights outside South Korea to a c-Mer proto-oncogene tyrosine kinase (MERTK) inhibitor that is in preclinical development to treat cancer.

The Korean biotech deferred questions about the compound's name and development timeline to AbbVie, which declined to provide details. Neither responded to an inquiry about which partner will lead development...